NASDAQ:AKBA - Akebia Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Akebia Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.03 +0.25 (+3.21 %) (As of 01/20/2020 07:46 AM ET) Add Compare Today's Range$7.84Now: $8.03▼$8.0850-Day Range$5.56MA: $6.50▼$8.0352-Week Range$2.99Now: $8.03▼$9.30Volume1.77 million shsAverage Volume1.20 million shsMarket Capitalization$955.09 millionP/E RatioN/ADividend YieldN/ABeta1.77 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA Previous Symbol CUSIPN/A CIK1517022 Webhttp://www.akebia.com/ Phone617-871-2098Debt Debt-to-Equity Ratio0.06 Current Ratio1.34 Quick Ratio0.82Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$207.74 million Price / Sales4.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.44 per share Price / Book1.48Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-143,590,000.00 Net Margins-75.39% Return on Equity-32.74% Return on Assets-20.44%Miscellaneous Employees324 Outstanding Shares118,940,000Market Cap$955.09 million Next Earnings Date3/24/2020 (Estimated) OptionableOptionable Receive AKBA News and Ratings via Email Sign-up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:AKBA Rates by TradingView Akebia Therapeutics (NASDAQ:AKBA) Frequently Asked Questions What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics Inc (NASDAQ:AKBA) released its quarterly earnings data on Tuesday, November, 12th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.09. The biopharmaceutical company earned $91.98 million during the quarter, compared to the consensus estimate of $93.94 million. Akebia Therapeutics had a negative net margin of 75.39% and a negative return on equity of 32.74%. View Akebia Therapeutics' Earnings History. When is Akebia Therapeutics' next earnings date? Akebia Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Akebia Therapeutics. What price target have analysts set for AKBA? 5 equities research analysts have issued twelve-month target prices for Akebia Therapeutics' stock. Their forecasts range from $9.00 to $17.00. On average, they expect Akebia Therapeutics' stock price to reach $13.80 in the next year. This suggests a possible upside of 71.9% from the stock's current price. View Analyst Price Targets for Akebia Therapeutics. What is the consensus analysts' recommendation for Akebia Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akebia Therapeutics. What are Wall Street analysts saying about Akebia Therapeutics stock? Here are some recent quotes from research analysts about Akebia Therapeutics stock: 1. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/21/2019) 2. HC Wainwright analysts commented, "We continue to believe that positive outcomes, on both safety and efficacy, from all four studies is highly likely, and with data directly comparing its outcomes to the current standard of care in both DD and NDD patients, we continue to believe Akebia is well positioned for clinical, regulatory and commercial success. Affirm Buy. $17 PT. We employ a rNPV model, driven by U.S. sales of vadadustat (early 2022 launch, 75% POS, $2.5B peak U.S. sales) and Auryxia (peak sales of $409M in 2024) out to 2028 (zero terminal value) discounted at 12.5%. Risks to our investment thesis and target price include: (1) failure in pivotal Phase 3 vadadustat studies; (2) failure to secure regulatory approval of vadadustat; (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing; and (4) intellectual property opposition." (9/9/2019) Has Akebia Therapeutics been receiving favorable news coverage? News headlines about AKBA stock have been trending positive on Monday, according to InfoTrie. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akebia Therapeutics earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Akebia Therapeutics. Who are some of Akebia Therapeutics' key competitors? Some companies that are related to Akebia Therapeutics include GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH), Intercept Pharmaceuticals (ICPT), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), PTC Therapeutics (PTCT), Taro Pharmaceutical Industries (TARO), Axsome Therapeutics (AXSM), Agios Pharmaceuticals (AGIO), Apellis Pharmaceuticals (APLS), Alkermes (ALKS), Zai Lab (ZLAB), Uniqure (QURE), Genmab A/S (GMAB) and Biohaven Pharmaceutical (BHVN). What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Chesapeake Energy (CHK), FireEye (FEYE), TherapeuticsMD (TXMD), Energy Transfer LP Unit (ET), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP), Bank of America (BAC) and Flexion Therapeutics (FLXN). Who are Akebia Therapeutics' key executives? Akebia Therapeutics' management team includes the folowing people: Mr. John P. Butler MBA, CEO, Pres & Director (Age 55)Mr. Jason A. Amello, Sr. VP, CFO & Treasurer (Age 51)Dr. Rita Jain, Sr. VP & Chief Medical Officer (Age 57)Ms. Nicole R. Hadas, SVP, Chief Legal Officer & Sec. (Age 46)Mr. Douglas Jermasek, VP of Marketing & Strategy Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Lincoln Capital Corp (0.02%), FNY Investment Advisers LLC (0.01%) and Assenagon Asset Management S.A. (0.01%). Company insiders that own Akebia Therapeutics stock include Duane Nash, John P Butler, Steven C Gilman and Steven Keith Burke. View Institutional Ownership Trends for Akebia Therapeutics. Which institutional investors are buying Akebia Therapeutics stock? AKBA stock was purchased by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Assenagon Asset Management S.A. and Lincoln Capital Corp. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman and Steven Keith Burke. View Insider Buying and Selling for Akebia Therapeutics. How do I buy shares of Akebia Therapeutics? Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $8.03. How big of a company is Akebia Therapeutics? Akebia Therapeutics has a market capitalization of $955.09 million and generates $207.74 million in revenue each year. The biopharmaceutical company earns $-143,590,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Akebia Therapeutics employs 324 workers across the globe.View Additional Information About Akebia Therapeutics. What is Akebia Therapeutics' official website? The official website for Akebia Therapeutics is http://www.akebia.com/. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected] MarketBeat Community Rating for Akebia Therapeutics (NASDAQ AKBA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 341 (Vote Outperform)Underperform Votes: 286 (Vote Underperform)Total Votes: 627MarketBeat's community ratings are surveys of what our community members think about Akebia Therapeutics and other stocks. Vote "Outperform" if you believe AKBA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKBA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2020 by MarketBeat.com StaffFeatured Article: Google Finance Portfolio
